Skip to main content

Amoroso Michael's Form 4 filing

Precision Biosciences IncDTIL · filed Jan 22, 2026

Accession no.
0001628280-26-003149
Filed
Jan 22, 2026
Trade date
Jan 20-22, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $145.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Amoroso MichaelCIK 0001830874Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 20, 2026Common StockMOption exerciseAcquired+8,888–F2–124,463Direct
Jan 20, 2026Common StockMOption exerciseAcquired+37,069–F2–161,532Direct
Jan 20, 2026Common StockMOption exerciseAcquired+69,421–F2–230,953Direct
Jan 22, 2026Common StockSSaleDisposed−34,799$4.17F4−$145,111.83196,154Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 20, 2026Common StockMOption exerciseDisposed−8,888$0.00$00Direct
Jan 20, 2026Common StockMOption exerciseDisposed−37,069$0.00$037,069Direct
Jan 20, 2026Common StockMOption exerciseDisposed−69,421$0.00$069,421Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Referenced by the price of 3 transactions in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)